Inside FDA’s New Gene and Cell Therapy Guidances

In January 2020, the agency finalized six clinical development and manufacturing guidance documents and drafted new guidance on what would qualify new gene therapies as orphan drugs.

Since 2017, FDA has approved four gene therapies, and regulators expect the number of gene and cell therapies under development to increase dramatically.

Read this article in BioPharm International’s March 2020 Regulatory Sourcebook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook, March 2020
March 2020
Pages: 8–11

Citation

When referring to this article, please cite it as A. Shanley, “Inside FDA’s New Gene and Cell Therapy Guidances," BioPharm International Regulatory Sourcebook eBook (March 2020).

Articles in this issue

over 5 years ago

Article

Resources, Guidelines, and Guidance Documents

over 5 years ago

Article

Regulatory and Standard Setting Organizations

over 5 years ago

Article

Is There a “New Normal” for Drug Quality?

over 5 years ago

Article

Monograph Development: Why and When to Participate (eBook)

over 5 years ago

Article

Pharmacopoeia Compliance: Putting It All Together; What Is on the Horizon (eBook)

over 5 years ago

Article

A Practical Approach to Pharmacopoeia Compliance (eBook)

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!